Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pilocarpine hydrochloride
Drug ID BADD_D01771
Description A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.
Indications and Usage For the treatment of radiation-induced dry mouth (xerostomia) and symptoms of dry mouth in patients with Sjögrens syndrome. A pilocarpine ophthalmic solution is indicated for the treatment of presbyopia in adults.[L39015]
Marketing Status approved; investigational
ATC Code S01EB01; N07AX01
DrugBank ID DB01085
KEGG ID D02200
MeSH ID D010862
PubChem ID 5909
TTD Drug ID D06HLY
NDC Product Code 0228-2837; 17478-223; 63279-100; 59212-775; 61314-204; 69238-1746; 69292-265; 71335-2094; 38779-0182; 16714-121; 59651-224; 61314-206; 0527-1407; 68084-928; 69238-1747; 12538-1921; 69205-001; 59651-225; 61314-203; 0074-7098; 17478-226; 50268-652; 59212-705; 63629-2099; 0527-1313; 16714-122; 63629-8351; 69238-1745; 82133-200; 17478-224; 0228-2801; 60219-5922
UNII 0WW6D218XJ
Synonyms Pilocarpine | Isoptocarpine | Salagen | Pilocarpine Hydrochloride | Hydrochloride, Pilocarpine | Pilocarpine, Monohydrochloride, (3S-cis)-Isomer | Pilocarpine Nitrate | Nitrate, Pilocarpine | Pilocarpine Mononitrate, (3S-cis)-Isomer | Isopilocarpine | Ocusert
Chemical Information
Molecular Formula C11H17ClN2O2
CAS Registry Number 54-71-7
SMILES CCC1C(COC1=O)CC2=CN=CN2C.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vaginal haemorrhage21.08.01.001; 24.07.03.005--
Vaginal infection21.14.02.002; 11.01.10.002--
Viral infection11.05.04.001--Not Available
Vision blurred17.17.01.010; 06.02.06.0070.082749%
Visual acuity reduced06.02.10.012; 17.17.01.0110.008319%
Visual field defect17.17.01.001; 06.02.07.0030.009062%Not Available
Visual impairment06.02.10.0130.149898%Not Available
Vitreous detachment12.01.04.005; 06.09.01.0020.050808%Not Available
Vitreous floaters06.09.01.0050.043528%
Vitreous haemorrhage06.10.03.001; 24.07.05.0050.004011%
Vomiting07.01.07.003--
Vulvovaginal candidiasis21.14.02.003; 11.03.03.005--Not Available
White blood cell count abnormal13.01.06.028--Not Available
Yawning22.12.03.037--Not Available
Macular hole06.09.03.009--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Eye pruritus06.04.05.0060.005051%Not Available
Ocular discomfort06.08.03.0080.010102%Not Available
Musculoskeletal stiffness15.03.05.027--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Affect lability19.04.01.001--Not Available
Nuchal rigidity17.05.02.006; 15.05.04.005--Not Available
Hot flush21.02.02.001; 08.01.03.027; 24.03.01.0050.002228%
White blood cell disorder01.02.05.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Lacrimal disorder06.08.02.005--Not Available
Blood disorder01.05.01.004--Not Available
Increased bronchial secretion22.12.01.002--Not Available
Metamorphopsia17.17.01.020; 06.02.06.0140.005051%Not Available
Vulvovaginal mycotic infection21.14.02.004; 11.03.05.004--Not Available
The 8th Page    First    Pre   8 9    Next   Last    Total 9 Pages